Equity Profile

CRSP

CRISPR Therapeutics AG

Health CareBiotechnology$5.0B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines using CRISPR technology. With a market cap of $5 billion, it operates in the health care sector, aiming to address serious diseases through innovative therapies.

Key Metrics to Watch

Research and Development Expenses

Investments in R&D are crucial for advancing CRISPR's therapies and maintaining competitive advantage.

N/A

Clinical Trial Progress

Updates on clinical trials can significantly impact investor sentiment and stock performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1-2026, CRISPR reported an EPS of -$1.28, missing estimates by 12.38%. The stock reacted positively, gaining 3.78% the following day.

Management Promises & Guidance

Focus on advancing key clinical trials.
Commitment to strategic partnerships to enhance research capabilities.
Continued investment in innovative gene-editing technologies.

Expectations

Wall Street Expectations

Overall expectations are mixed as CRISPR has a history of earnings surprises. Investors are keen to see if the company can improve its financial performance.

Bull Case

If CRISPR can demonstrate significant progress in clinical trials and secure new partnerships, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations in R&D spending or clinical advancements, it may face negative investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of key clinical trials?

Investors will closely watch for any advancements or delays, as these can significantly impact the company's valuation.

Will CRISPR announce any new partnerships or collaborations this quarter?

New partnerships could enhance CRISPR's capabilities and resources, which is critical for its growth strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for CRISPR's clinical advancements, which could lead to a more favorable outlook than currently priced in.

Supporting Evidence

Options are pricing a 26.4% move, indicating expectations of significant volatility that may not materialize.

The historical EPS beat rate is only 38%, suggesting that the market may be overly cautious about potential upside.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around CRISPR's ability to innovate and expand its pipeline through successful R&D and partnerships.

Bull Confirmed If

Demonstrating significant progress in clinical trials with positive data outcomes.

Bear Confirmed If

Failure to advance key clinical trials or secure new partnerships.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting heightened volatility around the earnings report.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations with positive trial data, history suggests the stock could rise around 3.6% based on past reactions.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see muted movement as investors reassess.

Miss

If CRISPR misses expectations, history suggests a potential decline of around 0.68% based on past performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Details on any partnerships or collaborations that may have been established.
3Insights into R&D spending and future investment plans.
4Management's outlook on the competitive landscape in gene editing.
5Any commentary on regulatory challenges or milestones.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Key Metrics to Watch

Research and Development Expenses

Investments in R&D are crucial for advancing CRISPR's therapies and maintaining competitive advantage.

N/A

Clinical Trial Progress

Updates on clinical trials can significantly impact investor sentiment and stock performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1-2026, CRISPR reported an EPS of -$1.28, missing estimates by 12.38%. The stock reacted positively, gaining 3.78% the following day.

Management Promises & Guidance

Focus on advancing key clinical trials.
Commitment to strategic partnerships to enhance research capabilities.
Continued investment in innovative gene-editing technologies.

Expectations

Wall Street Expectations

Overall expectations are mixed as CRISPR has a history of earnings surprises. Investors are keen to see if the company can improve its financial performance.

Bull Case

If CRISPR can demonstrate significant progress in clinical trials and secure new partnerships, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations in R&D spending or clinical advancements, it may face negative investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of key clinical trials?

Investors will closely watch for any advancements or delays, as these can significantly impact the company's valuation.

Will CRISPR announce any new partnerships or collaborations this quarter?

New partnerships could enhance CRISPR's capabilities and resources, which is critical for its growth strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for CRISPR's clinical advancements, which could lead to a more favorable outlook than currently priced in.

Supporting Evidence

Options are pricing a 26.4% move, indicating expectations of significant volatility that may not materialize.

The historical EPS beat rate is only 38%, suggesting that the market may be overly cautious about potential upside.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around CRISPR's ability to innovate and expand its pipeline through successful R&D and partnerships.

Bull Confirmed If

Demonstrating significant progress in clinical trials with positive data outcomes.

Bear Confirmed If

Failure to advance key clinical trials or secure new partnerships.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting heightened volatility around the earnings report.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations with positive trial data, history suggests the stock could rise around 3.6% based on past reactions.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see muted movement as investors reassess.

Miss

If CRISPR misses expectations, history suggests a potential decline of around 0.68% based on past performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any new data.
2Details on any partnerships or collaborations that may have been established.
3Insights into R&D spending and future investment plans.
4Management's outlook on the competitive landscape in gene editing.
5Any commentary on regulatory challenges or milestones.